Physician Photo

Chin-Lee Wu, MD, PhD

Associate Pathologist, Massachusetts General Hospital

Associate Professor of Pathology, Harvard Medical School

Dr. Wu is a Genitourinary Pathology specialist with interests in urologic cancers, prostate cancers, kidney cancer, and bladder cancer.

Department of Pathology


  • Cancer Center
  • Parathyroid Tumors
  • Kidney Cancer
  • Prostate Cancer
  • Thyroid Tumors
  • Testicular Cancer
  • Bladder Cancer
  • Adrenal Tumors
  • Endocrine Tumors
  • Head & Neck Cancers
  • Genitourinary Oncology
Clinical Interests
Genitourinary pathology
Head and Neck Pathology
Boston: Massachusetts General Hospital
Medical Education
MD, First Military Medical University
PhD, Medical College of Wisconsin
Residency, Massachusetts General Hospital
Fellowship, Massachusetts General Hospital
Board Certifications
Anatomic Pathology, American Board of Pathology
Foreign Languages
Patient Age Group
Accepting New Patients
Accepting New Patients


Dr. Wu is recognized internationally as a Genitourinary Pathology specialist. In recent years he developed a genitourinary tumor bank for teaching and research purposes. He consults as needed for particularly difficult urologic pathology specimens encountered by other staff pathologists who do not specialize in prostate, bladder and kidney cancer. Is a member of the Dana Farber-Harvard Cancer Center research team, and has his research laboratory in the Pathology Department at Massachusetts General Hospital.


The Wu laboratory is jointly supported by the departments of urology and pathology at Massachusetts General Hospital. Research is focused on studies of molecular biomarkers in urologic tumors including cancers of the prostate, bladder and kidney. The long-term goal of our studies is to develop new diagnostic methods and therapeutic regimens. A major focus of the lab is to identify gene expression profiles associated with development, diagnosis and prognosis of prostate cancer. We have used laser capture micro-dissection techniques and DNA microarray technology to identify a group of genes whose expression can be used to predict the outcome of patients diagnosed with prostate cancer. We are in the process of developing a new gene-based diagnostic test to guide clinical management of prostate cancer. 

Another project in the laboratory is aimed at improving imaging techniques in prostate cancer. Dr. McDougal, Dr. Leo Cheng and I have identified a metabolomic signature of prostate cancer. We are applying this signature to develop an in-vivo imaging technique for patients with prostate cancer. With this new imaging technology, we hope to be able to better stage localized prostate cancer and quantify the volume of prostate cancer in-vivo See details at the Wu Lab. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Wu's profile at the Harvard Clinical and Translational Science Center.



View my most recent publications at PubMed

  1. Age and Obesity Promote Methylation and Suppression of 5-Alpha Reductase 2- Implications for Personalized Therapy in Benign Prostatic Hyperplasia. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. J Urol. 2015 Apr 24. pii: S0022-5347(15)03861-6. doi: 10.1016/j.juro.2015.04.079. [Epub ahead of print]
  2. Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong W, Olumi A, Young RH, Wu CL.Hum Pathol. 2015 Mar 11. pii: S0046-8177(15)00079-9. doi: 10.1016/j.humpath.2015.02.013. [Epub ahead of print]
  3. Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer.Liang YX, Mo RJ, He HC, Chen JH, Zou J, Han ZD, Lu JM, Cai C, Zeng YR, Zhong WD, Wu CL. Oncol Rep. 2015 May;33(5):2648-54. doi: 10.3892/or.2015.3870. Epub 2015 Mar 20.

Gene-expression signature may signify risk for recurrence, metastasis in prostate cancer

A team led by MGH researchers has identified a genetic signature that may reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed, the genetic risk index also may help distinguish tumors that require aggressive treatment from those that can safely be monitored.

Pathology Associates
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-2967
Fax: 617-726-7474